Foundation successfully hosted its 4th ICPO Forum for Theranostics in Precision Oncology on May 15 & 16, 2025 in Garching ...

Over 220 experts from around the globe came together to shape the future of radiotheranostics for better cancer patient outcomes Wiesbaden - May 26, 2025 - The International Centers for Precision ...

Several strategies have been used to inhibit VEGF signaling (Table). Broadly ... hepatocellular carcinoma, colorectal cancer, gastrointestinal stromal tumor, pancreatic neuroendocrine tumor, soft ...

A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been ...

A new combination therapy that pairs a radiopharmaceutical (177 Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been deemed feasible and tolerable for neuroendocrine cancer patients.

177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is a mainstay strategy for low- to intermediate-grade metastatic neuroendocrine tumor patients. While this targeted radiopharmaceutical ...

11, 2001, died May 18 after an eight-year battle with head and neck cancer. Vales’ fight against the rare neuroendocrine tumor ended the day after her 48th birthday. She was working as a donor ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...